GlobeNewswire

New cyber-risk conference coming to Bermuda in 2018

Dela

HAMILTON, Bermuda, Feb. 21, 2018 (GLOBE NEWSWIRE) -- A new Bermudian edition of a successful North American cyber-risk conference will be held later this year, the Bermuda Business Development Agency (BDA) has announced.

The inaugural International Cyber Risk Management Conference (ICRMC) Bermuda, presented by Canada's MSA Research Inc, will take place December 6-7 at the Hamilton Princess & Beach Club, following a BDA invitation to bring the event to the island. ICRMC Bermuda will be designed for corporate risk managers, corporate counsel, auditors, CISOs, CSOs, and CTOs, governance and claims professionals, insurers, reinsurers, insurance brokers and service providers. The BDA will be signature sponsor of the two-day conference that follows the company's popular Toronto event, happening April 11-12.

"We are proud to bring ICRMC to Bermuda, the 'World's Risk Capital,' where we, with the support of a stellar steering committee, will focus on cyber risk with an emphasis on re/insurance and risk-transfer solutions," said Joel Baker, President and CEO of both MSA, the leading provider of Canadian insurance financial data, and the National Insurance Conference of Canada. Baker is also CEO of Canada's catastrophe index provider, CatIQ Inc.

Baker and his ICRMC team visited Bermuda over the past week to plan the December event, meet with sponsors and local members of its advisory committee, and also speak about their event plans with leaders of the island's risk-industry groups, including the Bermuda Insurance Management Association (BIMA), the Association of Bermuda International Companies (ABIC), and the Association of Bermuda Insurers & Reinsurers (ABIR).

"We're delighted to be working with the BDA team and a strong mix of world-class Bermudian, US and Canadian talent to shape this unique event," added Baker, who regularly attends the ILS Bermuda Convergence conference each fall, and also visited Bermuda in 2016 to participate in an educative session on Canada's risk-management industry hosted by ABIR. "ICRMC is the Bermudian edition of our Canadian event, a vendor-neutral gathering designed to serve the global risk management community. There's no better location than Bermuda, given its central place in the insurance, reinsurance and insurance-linked securities (ILS) arena," Baker added.

"We're extremely proud to have brought another industry conference to Bermuda, particularly one of this calibre that also provides a boost to the island's hospitality industry during the winter months," said Jereme Ramsay, BDA Business Development Manager for the risk sector. "I met Joel in Bermuda, and we got talking about this last year. It seemed a natural fit for the ICRMC team to bring their successful conference to this market-and he agreed."

Programming for ICRMC Bermuda will be shaped by a world-class advisory committee made up of cyber-risk subject matter experts from the fields of information technology, insurance and risk management, law, audit and compliance, governance, and public policy. The committee features several industry professionals from the Bermuda market, including: Joshua Alvera, Public Policy & Regulatory Affairs Representative, ABIR; Carter Frith, SVP, FINPRO, Bowring Marsh (Bermuda); Chris Garrod, Director, Conyers Dill & Pearman; Giles Harlow, VP, Professional Risk Solutions, Aon (Bermuda); John Masters, AVP, Financial Lines, AIG; the BDA's Ramsay; and Errol Sinclair, Director of Forensic Technology & E-Discovery Services, KRyS Global.

International committee members include: Charles Carmakal, VP Mandiant/FireEye; Todd Daubert, Partner, Dentons US LLP; and Nick Galletto, Global Cyber Risk Services Leader, Deloitte LLP. Adam Segal, Director of Cyberspace and Digital Policy Program of the US-based Council on Foreign Relations, will emcee ICRMC Bermuda; Segal is also emcee of ICRMC Canada.

Now in its fourth year in Canada, ICRMC has earned a reputation as one of the world's top-rated cyber security forums, and attracted nearly 250 attendees in 2017. To combine promotion of both ICRMC events and raise awareness of the inaugural Bermuda conference, ICRMC is offering a 30-percent discount courtesy of the BDA to delegates looking to attend the Canadian conference. To take advantage of the special Toronto offer, use the discount code #BDA2018.

For more information on ICRMC Bermuda, contact Nancy Miller, nancy.miller@icrmc.com or visit http://bermuda.icrmc.com/

MEDIA CONTACT:

Rosemary Jones
Head of Communications & Marketing
rosemary@bda.bm
441 278-6558
441 337-4696

CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business here smooth and beneficial.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/af7986a1-907d-42d7-a613-72ca70dcf84a




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bermuda Business Development Agency (BDA) via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum